Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.

Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer. - Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000705

Enrollment

Registered

2007-05-14

Start date

2007-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

in patients with completely resected stage IB-IIIA non-small-cell

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients completely resected p-stage IB-IIIA non&#8211;small-cell lung cancer with acceptable baseline characteristics and an ECOG performance status of 0 or 1 were eligible

Exclusion criteria

Exclusion criteria: Patients with incomplete resection, wedge resection, clinically significant cardiac dysfunction, active infection, Varicella, or critical complications, neurologic or psychiatric disorders, and patients who had had other cancers treated within the previous five years were ineligible. Pregnant woman were also ineligible. Patients decided to be unsuitable by the doctor was ineligible.

Design outcomes

Primary

Measure	Time frame
treatment compliance rate is 70% or more.	—

Countries

Japan

Contacts

Public ContactKazuhito Funai

Hamamatsu University School of Medicine First Department of Surgery

kfunai@hmedc.or.jp

Outcome results